Spiraling Costs: Who Will Address the Role of Medicolegal Drivers?

Article

I think it is a real shame that inside the Beltway, both sides of the political arena have had neither the wisdom nor the courage to recognize and address the fact that medicolegal drivers will continue to push costs upward until someone takes the lead in tackling this issue.

Derek Raghavan, MD

Carolinas HealthCare System (CHS) has always taken care of indigent patients and has thus practiced the philosophy embedded in Michael Porter's more recent treatise on redefining health care. Thus CHS and its Levine Cancer Institute will continue to provide care to all patients with cancer and allied disorders. We recognize that costs need to be reduced and efficiencies and quality increased, and these objectives are embedded in our work.

I think it is a real shame that inside the Beltway, both sides of the political arena have had neither the wisdom nor the courage to recognize and address the fact that medicolegal drivers will continue to push costs upward until someone takes the lead in tackling this issue.

More on the Supreme Court Decision

Derek Raghavan
Bruce Minsky
Nora Janjan
Michael Glod
James B. Yu
Lawrence Wagman
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content